Initiate global double-blind placebo-controlled registration/confirmatory study
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Aug 2024
- Due
- 30 Jun 2025
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Planned global double-blind placebo-controlled registration/confirmatory study targeted to be initiated by mid- 2025”
What we found
Evidence strength A What the grades mean
The company did not initiate the global Phase 3 confirmatory study by mid-2025; subsequent filings indicate the initiation of screening and dosing was pushed to 2026.
-
A Larimar Therapeutics, Inc. 10-K filed 2026-03-19
“we plan to initiate screening in this Phase 3 study in the second quarter of 2026, with dosing of the first patient expected in mid-2026.” ✓ confirmed on the page
Market reaction: the shares moved +9.5% against the S&P 500 over the three sessions around the disclosure (18 Mar 2026 to 23 Mar 2026). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Initiate
- Deliverable
- Global double-blind placebo-controlled registration/confirmatory study
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-LRMR-003007 · Corrections policy